Projects per year
Personal profile
Area of Expertise
My laboratory is interested in developing and characterizing safe and effective drugs that can be used for the treatment of individuals afflicted with Parkinson’s disease, Alzheimer’s disease, schizophrenia, Tourette syndrome, and dystonia. We have also worked to develop drugs that can be used to assist in the rehabilitation of individuals who abuse cocaine. These studies have provided insights on the role of dopamine and sigma receptors in the brain.
Education/Academic qualification
BA in Chemistry, University of Illinois at Urbana-Champaign
BS in Microbiology, University of Illinois at Urbana-Champaign
PhD in Immunology, University of Pennsylvania
Fingerprint
Dive into the research topics where Robert Luedtke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
UNTHSC Summer Research Internship Program (SRIP)
Jones, H., Luedtke, R. & Vishwanatha, J.
NIDA: National Institute on Drug Abuse
15/04/18 → 28/02/23
Project: Research
-
Discovery of Functionally Selective Alzheimer's Disease Therapeutics
NIA: National Institute on Aging
15/09/17 → 31/05/22
Project: Research
-
Discovery of functionally selective Alzheimer's disease therapeutics
Luedtke, R., Schetz, J. & Luedtke, R.
15/09/17 → 31/05/22
Project: Research
-
Sigma 1 Receptor as a Target for Repetitive Concussive Brain Injury
Schreihofer, D., Luedtke, R. & Sumien, N.
1/08/16 → 30/04/18
Project: Research
-
-
Evaluation of substituted n-phenylpiperazine analogs as D3 vs. D2 dopamine receptor subtype selective ligands
Lee, B., Taylor, M., Griffin, S. A., McInnis, T., Sumien, N., Mach, R. H. & Luedtke, R. R., 1 Jun 2021, In: Molecules. 26, 11, 3182.Research output: Contribution to journal › Article › peer-review
Open Access -
Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes
Hayatshahi, H. S., Luedtke, R. R., Taylor, M., Chen, P. J., Blass, B. E. & Liu, J., 28 Jun 2021, In: Journal of Chemical Information and Modeling. 61, 6, p. 2829-2843 15 p.Research output: Contribution to journal › Article › peer-review
-
Interaction of ligands for pet with the dopamine d3 receptor: In silico and in vitro methods
Hsieh, C. J., Riad, A., Lee, J. Y., Sahlholm, K., Xu, K., Luedtke, R. R. & Mach, R. H., Apr 2021, In: Biomolecules. 11, 4, 529.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Ligand with two modes of interaction with the dopamine D2 receptor-an induced-fit mechanism of insurmountable antagonism
Sahlholm, K., Agren, R., Zeberg, H., Stepniewski, T. M. I., Benjamin Free, R., Reilly, S. W., Luedtke, R. R., Arhem, P., Ciruela, F., Sibley, D. R., Mach, R. H., Selent, J. & Nilsson, J., 7 Oct 2020, In: ACS Chemical Neuroscience. 11, 19, p. 3130-3143 14 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands
Chen, P. J., Taylor, M., Griffin, S. A., Amani, A., Hayatshahi, H., Korzekwa, K., Ye, M., Mach, R. H., Liu, J., Luedtke, R. R., Gordon, J. C. & Blass, B. E., 15 Sep 2019, In: Bioorganic and Medicinal Chemistry Letters. 29, 18, p. 2690-2694 5 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations